Type B adverse drug reactions (ADRs) are often serious, limit the usefulness of drugs that are otherwise effective, and increase the risks of drug development as they often lead to postmarketing withdrawal. There is evidence that susceptibility to at least some Type B ADRs is under strong genetic influence. Identifying genes in which variation influences susceptibility has obvious practical value for genetic testing and might also make it easier to screen molecules likely to cause ADRs at an early stage of the drug development process. Research in this area is hampered by the lack of a resource in which to study genetic determinants of susceptibility to Type B ADRs. As serious Type B ADRs are rare, case-control designs are the most frequently-used approach. The EUDRAGENE collaboration seeks to develop a resource using an international collaboration. This will provide a basis for adverse drug susceptibility genome association-wide studies using tag single nucleotide polymorphisms, or a direct approach using putative functional polymorphisms.
Most research on the genetic basis of susceptibility to adverse drug reactions (ADRs) has focused on studying dose-dependent reactions that are predictable on the basis of the drug's known pharmacological actions. These Type A reactions are relatively common, and there has been considerable progress in identifying genes that determine susceptibility through effects on drug metabolism [1, 2] . There has been little research on the genetic basis of susceptibility to Type B reactions: idiosyncratic reactions that are not necessarily dose-dependent. Only a few genetic causes of such reactions have been identified [3] : mutations in the RYR1 gene predict susceptibility to anesthetic-induced malignant hyperthermia, and a polymorphism in the G6PD gene predicts susceptibility to druginduced hemolytic anemia. Serious idiosyncratic adverse reactions are necessarily rare: a drug that commonly causes such reactions will not be licensed. Of all ADRs occurring in hospitalized patients in the USA, approximately a quarter are Type B reactions [4] .
Why studying the genetics of Type B adverse drug reactions is important Although serious Type B adverse reactions are rare, they are of considerable importance to human health because they may severely limit the use of an otherwise effective drug (such as clozapine, which causes agranulocytosis in fewer than 1% of patients) or because they may lead to withdrawal of a drug (such as cerivastatin, associated with 52 reported deaths from rhabdomyolysis and for rofecoxib found to be associated with increased risk for myocardial infarction and stroke) after the costs of development and bringing it to market have been incurred. Pharmaceutical risk management is being implemented in the EU as a means to reduce the probability of unanticipated regulatory decisions through the continuous assessment of benefit/risk. Further possibilities include identifying susceptible individuals through genetic testing, and greater understanding of these disease syndromes when they are not drug induced.
Aims of the EUDRAGENE project
The objective of the EUDRAGENE project, funded by the European Commission 5th Framework program, is to establish a freelyshared case-control collection of DNA samples, as a multicenter European collaboration. This will act as a resource for studying genetic predictors of ADRs, using the existing system for spontaneous reporting of suspected ADRs to national or regional pharmacovigilance centers.
How many cases are needed?
As Type B reactions are rare (<1%), and families containing multiple affected individuals are even rarer, family linkage studies cannot be used to find susceptibility genes. Using large cohorts or registries to study ADRs as proposed [5] would not yield sufficient cases. Case-control designs are a more efficient approach to studying genetic determinants of susceptibility to rare outcomes. A case-control study provides a valid estimate of risk or hazard ratio. As the exposure (genotype) is not affected by the onset of disease and can be measured without error, one limitation of case-control studies (biased measurement of exposure known as protopathic bias) does not apply. Selection bias is also less serious since the genotype does not influence referral or recruitment of cases and controls and can be overcome, as controls can be recruited from the same population at risk.
Simple power calculations are based on 90% power to detect association at p-values of less than 10 -6 , using the indirect 'haplotype-tagging' approach, utilizing selected SNPs to capture most of the common variation in the gene [6] . To detect a disease-associated variant that accounts for at least 25% of all cases, around 200-250 cases of each ADR under study are required.
Why is international collaboration necessary?
As most such ADRs are rare, a case-control design is the most frequently used approach, and a multicenter European collaboration is necessary as no single country will generate a sufficient number of cases of any given ADR within a reasonable time. National and regional pharmacovigilance systems provide a systematic means of case ascertainment. Table 1 shows the numbers of events reported over 1997-2002 in Europe for six classes of ADR that are of current interest. Rates show considerable variation between countries, possibly explained by differences in exposure and/or in reporting.
Adverse reactions studied (initial set)
The adverse reactions studied (initial set) include: [7] [8] [9] ) caused by all drug classes • Mefloquine-induced psychosis
Case definitions
Case definitions for each class of ADR have been compiled by a working group of EUDRA-GENE investigators, in consultation with other experts, based on internationally agreed criteria. Events are classified as drug exposed only where the temporal sequence from drug intake to onset is clear and following the exclusion of other known medical or environmental causes, supplemented with Naranjo criteria for estimating ADR probability.
Case ascertainment
All European countries have a system for spontaneous reporting of adverse reactions, supplemented by reports from drug manufacturers to regulatory agencies. Although pharmacovigilance remains the responsibility of national drug regulatory agencies, national systems are being harmonized through the European Medicines Evaluation Agency, which is compiling a Europewide database of reports of ADRs [101] . Even for serious ADRs there is considerable under-reporting [10] ; estimated reporting rates range from less than 10% [11, 12] to less than 1% [13] . In some, but not all countries, algorithms are applied to each report to assess the causal role of the drug. French pharmacovigilance systems are especially well developed, with mandatory reporting by physicians and follow up of individual cases by regional pharmacovigilance centers. In the UK, the Medicines and Healthcare Products Regulatory Agency (MHRA) has recently completed a review of access to data from the yellow card system, and indicated that data will be made available for researchers in the near future.
For certain classes of ADR, case ascertainment can be supplemented through hospital records: for instance to search for cases of LQTS. Although the final sample of cases may not be representative of all cases occurring in the population (due to under-reporting, restrictive case definition and nonresponse), this selection bias will not affect genetic associations unless there is population stratification, which can be dealt with in the statistical analysis [14] .
Collection of material from cases
For each report of a suspected ADR falling into one of the classes under study, a letter from the local investigator is forwarded to the physician who reported the ADR. This letter explains the objectives of the project, and asks the physician to help by inviting the patient to donate a blood sample for genetic studies. Patients are invited to complete a short questionnaire including demographic EUDRAGENE -SPECIAL REPORT information and medical history, to donate a blood sample, and to provide written consent for the use of medical records and the anonymized sample for genetic studies. Other data collected include the drug suspected to be the cause of ADR, the indication for which this drug was prescribed, a list of other medications taken concurrently, and relevant environmental exposures.
Selection of controls
Two possible sources of controls include general population controls and drug matched controls. One advantage of using population controls is the existence of several existing collections with consent to use of the anonymized DNA samples for genetic studies. A possible disadvantage of using population controls is that the case-control comparison is confounded by any genetic factors that are associated with factors for which the drug is prescribed. For example, individuals receiving statins are at higher risk of cardiovascular disease than population controls. In practice this is not a serious risk as most drugs are prescribed for broad indications, or there are several classes of drugs implicated that may cause the ADR. Databases of drug utilization and primary care have facilitated the identification of patients prescribed certain classes of drug [15] .
The main confounder in case-control studies is population stratification; methods exist to control for this, allowing elimination of almost all other confounding [14, 16, 102] . Genes which metabolize external substrates may display large frequency differentials within Europe which may act as confounders, unless adjusted for [17] .
Strategies for selecting candidate genes
Two main strategies are available for genetic association studies: direct (identifying polymorphisms likely to affect function) and indirect approaches (marker polymorphisms, and relying on detecting allelic associations with functional polymorphisms in the same gene).
The direct approach relies on the ability to identify libraries of functional polymorphisms using bioinformatics tools [103] . The indirect approach is efficient where allelic heterogeneity is low (only one or two disease-associated alleles in each of the genes that influence risk). One strategy for studies is based on the indirect approach, in which 4-10 SNPs in each gene are used to 'tag' the haplotypes and thus capture most of the common variation in the gene [6] . This approach exploits the genetic history of the European population, in which past constraint of population size has led to loss of haplotype diversity. The 'haplotype map' project initiated by the US National Institutes of Health facilitates the identification of 'haplotypetagging' SNPs [104] . Although tag SNPs can be used for multiple populations, different strategies will be required if haplotypes causing the ADR are extremely rare [18] .
As genotyping costs fall, whole-genome association studies (WGA) are becoming more feasible, provided that there is adequate statistical power to detect associations at stringent levels of significance that adjust for the multiple tests performed [19, 20] . Although technology has vastly improved in recent years, error rates remain constant. Ideally, cases and controls should be genotyped using the same platforms, to reduce differential error rates in genotype scoring that can bias results [21] . In practice it is often more practical to use controls that have already been genotyped, and new methods of statistical analyses may be required to overcome this problem.
For each class of ADR to be studied, there are several approaches to select candidate genes:
• Selection of functional polymorphisms in genes for drug transport and metabolism such as cytochrome P450 (CYP)2D6 and adenosine triphosphate-binding cassette (ABCB1 -MDR1, encoding the drug transporter P-glycoprotein) genes [22, 23] . One approach will explore SNPs in the CYP2D6 gene for which assays have been set up and individuals can be classified into four main groups
• Selection of genes causing Mendelian forms of the same syndrome; for example LQTS, for which causative genes have been identified. Common variants in these genes can be investigated as candidates for susceptibility to druginduced forms of the same syndrome. At least six genes in which mutations cause Mendelian forms of LQTS have been identified by family linkage studies: five encoding potassium channels and one encoding a sodium channel. A recent study identifying cases of drug-induced QT c prolongation and cardiac arrest in the Netherlands screened 4/45 eligible cases for genetic mutations and identified variants in potassium voltage-gated channel, subfamily H, member 2 (KCNH2), sodium channel, voltagegated, type Vα (SCN5A) and potassium voltage-gated channel, ISK-related family, member 1 (KCNE1) [24] . Not all individuals who harbor disease-causing mutations are affected [25] , and these mutations are rare in patients with drug-induced LQTS [26] , suggesting that the effects of these genes depend upon other modifier loci. Similarly, at least three different genes have been identified as causing Mendelian forms of agranulocytosis: elastase 2, neutrophil (ELA2) [27] , growth factor independent 1 (GFI1 -protooncogene which targets ELA2) [28] , granulocyte colony stimulating factor (GCSF) [29] and GCSF receptor (GSCFR) [30] and Janus kinase 2 (JAK2 -a tyrosine kinase involved in GCSF signaling) [31] .
• Genetic determinants of immune function including polymorphisms of cytokines, interleukins and human leukocyte antigen (HLA) haplotypes associated with idiosyncratic reactions, such as drug-induced hepatotoxicity [32] . Outlook: UK a future resource This international collaboration has been established on the basis that the case-control resource will be freely available to researchers in the participating countries, in the both the academic and industry sectors. As a condition of access to the samples, investigators will be required to submit all their genotype data to the main database, so that subsequent research can make use of data already acquired. Over the next few years more countries are expected to join the EUDRAGENE network, allowing the rate of case accrual to increase. Even with a multicenter European approach, the main challenges will be identifying cases.
Compliance with guidelines for research using human DNA samples
The computerization of primary care in the UK may facilitate the development of new and more rapid methods for detecting ADRs in clinical pactice with the creation of primary care databases with longitudinal medical records and drug prescription data covering several million people [33] . In principle, it is possible to exploit these databases for a more direct approach to the detection of associations between drugs and adverse events, as ascertainment of adverse events in these databases can be almost complete in practices with good systems for collecting diagnostic data. For case-control comparisons, cases and controls from such databases can also be matched for clinical indication. In the longer term, the development of integrated health records by the National Health Service (NHS) could allow the methods to be applied to a much wider population and thus greatly improve the detection rates of ADRs.
The establishment of EUDRAGENE provides a unique case-control resource to study the genetic basis of ADRs, including meta-analyses. This collection will provide the basis for studies of association with candidate genes and future genome-wide association studies. We anticipate that the resource will continue for several years, based on the issues of current concern.
